QSAM Biosciences Appoints Charles J. Link, Jr., M.D., Experienced Biotech Executive and Innovator, to Board of Directors
Austin, TX, Feb. 16, 2021 (GLOBE NEWSWIRE) -- QSAM Biosciences Inc. (OTCQB: [...]
QSAM Biosciences Closes Series B Preferred Private Placement; $2.5 Million in New Capital to Fund Upcoming Clinical Trials
Austin, Texas, Jan. 28, 2021 (GLOBE NEWSWIRE) -- QSAM Biosciences Inc. (OTCQB: [...]
QSAM Biosciences Receives Favorable Safety Results in Study for its Leading Radiopharmaceutical Drug Candidate
Palm Beach, FL, Jan. 21, 2021 (GLOBE NEWSWIRE) -- QSAM Biosciences [...]
QSAM Biosciences Receives Notice of Allowance for European Patent and Expands Licensed IP Portfolio
Palm Beach, FL, Dec. 10, 2020 (GLOBE NEWSWIRE) -- QSAM Biosciences [...]
QSAM Biosciences Issues Letter from New CEO; Presents Opportunities Ahead for Company
Palm Beach, FL, Nov. 24, 2020 (GLOBE NEWSWIRE) -- The [...]
QSAM Biosciences Advances Plan of Separation from Legacy Business
Palm Beach, FL, November 10, 2020 – QSAM Biosciences Inc. [...]
Q2Earth Changes Name to QSAM Biosciences, Inc.; Will Commence Trading Under Symbol QSAM in 20 Business Days
Palm Beach, FL; September 10, 2020 – Q2Earth Inc. [...]
Q2Earth Signs Exclusive Option Agreement to License Promising Drug to Treat Bone Cancer in Children
Palm Beach, FL, Jan. 22, 2020 (GLOBE NEWSWIRE) -- Q2Earth, [...]